Pfizer deepens degrader footprint, Novartis taps China’s Baiyu, and more

Pfizer has expanded its protein degradation toolbox, this time via a molecular glue deal with Triana.

For $49 million in up front and up to $1.5 billion in milestones, Pfizer Inc. (NYSE:PFE) has the exclusive option to license molecular glue degraders, for cancer and other diseases, that  Triana Biomedicines Inc. will discover through its target-first and proximity-first discovery platform. The platform uses a protein-protein pairing engine to match E3 ligases to specific target proteins, then identify small molecules that promote their interaction. ...